4DMT Announces ASRS Presentation on 4D-150 Program
Key Takeaways
- 4D Molecular Therapeutics announced a podium presentation on 4D-150 at ASRS 44 in Montreal, Canada.
- The listed session topic describes a two-year follow-up from the PRISM Phase 2b clinical trial in broad neovascular AMD and identifies 4D-150 as an investigational intravitreal gene therapy.
- Carl Awh, MD, FASRS, of Tennessee Retina is scheduled to present the Saturday session, and the company says the presentation will be posted on its website.
Carl Awh, MD, FASRS, of Tennessee Retina is listed as the presenter for the podium session. The session description identifies PRISM as a Phase 2b clinical trial and 4D-150 as an investigational intravitreal gene therapy, with follow-up in a broad neovascular AMD population.
The company describes itself as a late-stage biotechnology company and identifies the 4D-150 program as its lead product candidate. Wet age-related macular degeneration is named as the lead indication for 4D-150, and the company places that effort in Phase 3. The same background identifies diabetic macular edema as the second indication under evaluation. In company-described terms, 4D-150 is designed as a backbone therapy intended to provide multi-year sustained delivery of anti-VEGF biologics with one intravitreal injection.
The company says the presentation will also be available on the 4DMT website after the meeting session. It also notes that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulators. Another company statement says no representation is made regarding safety or effectiveness for the uses under study.